These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38747453)

  • 41. A pharmacokinetic/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation.
    Liao S; Ge T; Zhu L; Zhao Y; Yang J; Xu G
    Pharmazie; 2015 May; 70(5):306-9. PubMed ID: 26062298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis.
    Kirbs C; Kluwe F; Drescher F; Lackner E; Matzneller P; Weiss J; Zeitlinger M; Kloft C
    Eur J Pharm Sci; 2019 Apr; 131():218-229. PubMed ID: 30731238
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
    Zhu L; Brüggemann RJ; Uy J; Colbers A; Hruska MW; Chung E; Sims K; Vakkalagadda B; Xu X; van Schaik RH; Burger DM; Bertz RJ
    J Clin Pharmacol; 2017 Feb; 57(2):235-246. PubMed ID: 27432796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
    Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
    Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined Effect of
    Chen J; Wu Y; He Y; Feng X; Ren Y; Liu S
    Front Pediatr; 2022; 10():846411. PubMed ID: 35386257
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections.
    Wang T; Zhu H; Sun J; Cheng X; Xie J; Dong H; Chen L; Wang X; Xing J; Dong Y
    Int J Antimicrob Agents; 2014 Nov; 44(5):436-42. PubMed ID: 25239277
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.
    Calcagno A; Baietto L; Pagani N; Simiele M; Audagnotto S; D'Avolio A; De Rosa FG; Di Perri G; Bonora S
    Pharmacogenomics; 2014 Jul; 15(10):1281-6. PubMed ID: 25155930
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients.
    Huang X; Zhou Y; Zhang J; Xiang H; Mei H; Liu L; Tong L; Zeng F; Huang Y; Zhou H; Zhang Y
    Br J Clin Pharmacol; 2022 Oct; 88(10):4515-4525. PubMed ID: 35508605
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [CYP2C19 genetic polymorphism and monitoring voriconazole plasma concentrations in the treatment and prevention of invasive fungal disease for hematological patients].
    Qu HL; Guo DD; Xu T; Li Z; Yin J; Tian XP; Kong DQ; Zhu XM; Miao LY; Wu DP; Tang XW
    Zhonghua Xue Ye Xue Za Zhi; 2018 Mar; 39(3):202-206. PubMed ID: 29562464
    [No Abstract]   [Full Text] [Related]  

  • 50. Association of
    Song Y; Jia MX; Yang G; Feng XY; Yin DH; Kang JB; Zhao Q; Duan JJ
    Per Med; 2020 Jan; 17(1):15-22. PubMed ID: 31797717
    [No Abstract]   [Full Text] [Related]  

  • 51. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.
    Li X; Yu C; Wang T; Chen K; Zhai S; Tang H
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1185-1193. PubMed ID: 27388292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype.
    Bennis Y; Bodeau S; Bouquié R; Deslandes G; Verstuyft C; Gruson B; Andréjak M; Lemaire-Hurtel AS; Chouaki T
    Br J Clin Pharmacol; 2015 Oct; 80(4):782-4. PubMed ID: 26138512
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.
    Moriyama B; Jarosinski PF; Figg WD; Henning SA; Danner RL; Penzak SR; Wayne AS; Walsh TJ
    Pharmacotherapy; 2013 Mar; 33(3):e19-22. PubMed ID: 23400848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole.
    He HR; Sun JY; Ren XD; Wang TT; Zhai YJ; Chen SY; Dong YL; Lu J
    Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):811-9. PubMed ID: 25515945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children.
    Espinoza N; Galdames J; Navea D; Farfán MJ; Salas C
    Sci Rep; 2019 Jun; 9(1):8863. PubMed ID: 31222084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the
    Ling J; Yang X; Dong L; Jiang Y; Zou S; Hu N
    Front Pharmacol; 2024; 15():1455721. PubMed ID: 39228522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.
    Hicks JK; Crews KR; Flynn P; Haidar CE; Daniels CC; Yang W; Panetta JC; Pei D; Scott JR; Molinelli AR; Broeckel U; Bhojwani D; Evans WE; Relling MV
    Pharmacogenomics; 2014 Jun; 15(8):1065-78. PubMed ID: 25084200
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Individualized treatment with voriconazole in the Chinese population: Inflammation level as a novel marker for dose optimization.
    Hao X; Li Y; Zhang Y; Bian J; Zhao J; Zhao Y; Hu L; Luo X; Yang C; Feng Y; Huang L
    Br J Clin Pharmacol; 2024 Feb; 90(2):440-451. PubMed ID: 37766511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration: data from a real-life clinical setting in the Chinese population.
    Li Y; Zhang Y; Zhao J; Bian J; Zhao Y; Hao X; Liu B; Hu L; Liu F; Yang C; Feng Y; Huang L
    J Chemother; 2024 May; 36(3):179-189. PubMed ID: 37599449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of cyclosporine a and polymorphisms in
    Zeng G; Shi L; Li H; Wang L; Zhu M; Luo J; Zhang Z
    Xenobiotica; 2020 May; 50(5):614-619. PubMed ID: 31573401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.